Literature DB >> 32524023

ATYPICAL RECURRENCE OF PARATHYROID CARCINOMA FOLLOWING INFLIXIMAB THERAPY IN A PATIENT WITH ULCERATIVE COLITIS.

Felona Gunawan, Elizabeth Holt.   

Abstract

OBJECTIVE: Parathyroid carcinoma (PTC) has a high rate of recurrence, which typically occurs within 5 years of diagnosis involving locoregional sites. Immunosuppressive therapies pose a theoretical increased risk of malignancy. We report an atypical case of PTC recurrence in a patient receiving infliximab therapy for ulcerative colitis (UC).
METHODS: Main diagnostic tests performed included calcium and parathyroid hormone (PTH) levels, computed tomography, and a venous sampling study.
RESULTS: A patient with PTC, who was "cured" by parathyroidectomy, presented with recurrent hypercalcemia 21 years after his initial diagnosis. He had recently been diagnosed with UC and was started on infliximab. His serum PTH level was elevated. After negative routine neck imaging studies and sestamibi scan, he underwent selective venous sampling with PTH measurements, which localized the source lesion to the thoracic wall. Subsequent imaging showed multiple left lung and pleural nodules, which were surgically resected. Hypercalcemia abated after surgery, but quickly returned and was recalcitrant to treatment with cinacalcet and zoledronic acid. Further imaging demonstrated recurrent lung metastases, some along the left diaphragm. He underwent 2 additional surgical resections, after which PTH and calcium levels normalized. Infliximab was replaced with vedolizumab for treatment of UC.
CONCLUSION: Atypical presentation of PTC may occur in the context of immunosuppressive therapy. Venous sampling with PTH measurements can aid in localization of atypical metastatic PTC. Additional surveillance for PTC recurrence may be prudent following the initiation of immunosuppressive therapy in patients with a history of PTC.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 32524023      PMCID: PMC7282279          DOI: 10.4158/ACCR-2019-0519

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  12 in total

Review 1.  Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis.

Authors:  E Kebebew; O H Clark
Journal:  Surg Oncol Clin N Am       Date:  1998-10       Impact factor: 3.495

Review 2.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

Review 3.  Parathyroid carcinoma.

Authors:  B Givi; J P Shah
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-05-26       Impact factor: 4.126

4.  Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.

Authors:  Nynne Nyboe Andersen; Björn Pasternak; Saima Basit; Mikael Andersson; Henrik Svanström; Sarah Caspersen; Pia Munkholm; Anders Hviid; Tine Jess
Journal:  JAMA       Date:  2014-06-18       Impact factor: 56.272

Review 5.  Parathyroid carcinoma.

Authors:  Abbas Al-Kurd; Michal Mekel; Haggi Mazeh
Journal:  Surg Oncol       Date:  2014-04-03       Impact factor: 3.279

6.  Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Authors:  Johan Askling; Ronald F van Vollenhoven; Fredrik Granath; Pauline Raaschou; C Michael Fored; Eva Baecklund; Christina Dackhammar; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Solbritt Rantapää-Dahlqvist; Tore Saxne; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2009-11

Review 7.  Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?

Authors:  Yuehong Chen; Marcia Friedman; Gang Liu; Atul Deodhar; Cong-Qiu Chu
Journal:  Cytokine       Date:  2016-09-26       Impact factor: 3.861

Review 8.  Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.

Authors:  Edward Shelton; David Laharie; Frank I Scott; Ronac Mamtani; James D Lewis; Jean-Frederic Colombel; Ashwin N Ananthakrishnan
Journal:  Gastroenterology       Date:  2016-04-01       Impact factor: 22.682

9.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.

Authors:  Maria A Lopez-Olivo; Jean H Tayar; Juan A Martinez-Lopez; Eduardo N Pollono; Jose Polo Cueto; M Rosa Gonzales-Crespo; Stephanie Fulton; Maria E Suarez-Almazor
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272

10.  An unusual mediastinal parathyroid carcinoma coproducing PTH and PTHrP: A case report.

Authors:  Chuangjie Cao; Chengyun Dou; Fuqin Chen; Yan Wang; Xiaoli Zhang; Hong Lai
Journal:  Oncol Lett       Date:  2016-05-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.